Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan
Viruses · 2025
DOI: 10.3390/v17030440 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Viruses, 2025. Verfasst von Marcello Trizzino und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico "P. Giaccone", 90127 Palermo,…. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Anti-HIV Agents, Emtricitabine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead.
Abstract (Originalsprache)
Background
Antiretroviral therapy has transformed HIV infection from a fatal disease to a chronic and manageable condition, but increasing health issues beyond acquired immunodeficiency syndrome, such as metabolic, liver, and cardiovascular diseases, have been observed. Furthermore, the increasing prevalence of HIV strains resistant to older antiretroviral regimens has necessitated a re-evaluation of treatment strategies.
Methods
We performed a retrospective, observational study to evaluate the long-term outcomes of an antiretroviral switch from a non-nucleoside reverse transcriptase inhibitor-based to bictegravir-based regimen; this study aimed to assess the impact of this antiretroviral switch on treatment adherence, the safety profile, and virologic outcomes. The secondary objectives were to analyze the changes in lipid, kidney function, liver function, and anthropometric parameters after switching.
Results
A total of 25 patients were included in this analysis; virologic suppression was maintained over time, with 100% of patients demonstrating undetectable viral loads at 6, 12, 24, and 36 months. In parallel, a significant increase in CD4+ cell count was observed after switching. No significant differences were observed compared to the previous therapy regarding anthropometric parameters or laboratory parameters. However, a significant reduction in liver steatosis, as assessed by Fibroscan, was observed. Conclusions: bictegravir-based regimens are a valid therapeutic option for people living with HIV, particularly for those with metabolic comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, 90127 Palermo, Italy.
- Palermo Fast-Track City, Casa dei Diritti, Via Libertà 45, 90143 Palermo, Italy.
ORCID-Profile: Marcello Trizzino, Luca Pipitò, Antonio Cascio
Förderung
- Gilead
Zitieren
APA
Trizzino, M., Gaudiano, R., Arena, D. M., Pipitò, L., Gioè, C., & Cascio, A. (2025). Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan. Viruses. https://doi.org/10.3390/v17030440
Vancouver
Trizzino M, Gaudiano R, Arena DM, Pipitò L, Gioè C, Cascio A. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan. Viruses. 2025. doi:10.3390/v17030440
BibTeX
@article{Trizzino2025,
author = {Trizzino, Marcello and Gaudiano, Roberta and Arena, Dalila Mimì and Pipitò, Luca and Gioè, Claudia and Cascio, Antonio},
title = {Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17030440}
}
EUVIMED